Chadé Severin, P.C.

Since joining Kirkland, Chadé has been involved in the following representations:

• Apogee Therapeutics in its pending sale to AbbVie for approximately $10.9 billion
• Catalyst Pharmaceuticals in its pending sale to Angelini Pharma for $4.1 billion
• KalVista Pharmaceuticals in its sale to Chiesi for $1.9 billion
• Amicus Therapeutics in its $4.8 billion sale to BioMarin
• Akero Therapeutics in its sale to Novo Nordisk for up to $5.2 billion

Prior to joining Kirkland, Chadé was involved in the following representations:

• SiteOne Therapeutics in its acquisition by Eli Lilly for up to $1 billion
• AspenTech in its $11 billion combination with the industrial software business of Emerson Electric and the special committee in its subsequent $7.2 billion sale to Emerson of all shares of AspenTech not already owned by Emerson
• Ambrx Biopharma in its $2 billion acquisition by Johnson & Johnson
• POINT Biopharma in its $1.4 billion acquisition by Eli Lilly
• Adtalem Global Education in the $1 billion sale of its financial services segment to a consortium of Wendel Group and Colibri Group
• Strongbridge Biopharma in its sale to Xeris Pharmaceuticals for $267 million
• Pandion Therapeutics in its sale to Merck & Co. for $1.85 billion
• Stemline Therapeutics in its sale to Menarini Group for up to $677 million
• Gilead Sciences in its $4.9 billion acquisition of Forty Seven
• ArQule in its sale to Merck for $2.7 billion
• Carbonite in its sale to OpenText for $1.42 billion
• Achillion in its sale to Alexion for up to $1.225 billion
• Alder BioPharmaceuticals in its sale to Lundbeck for up to $1.95 billion
• Array BioPharma in its $11.4 billion sale to Pfizer
• Carbonite in its $618.5 million acquisition of Webroot
• Juno Therapeutics in its $9 billion acquisition by Celgene
• Ultragenyx in its successful topping bid for Dimension Therapeutics
• Gilead Sciences in its $11.9 billion acquisition of Kite Pharma